Journal of Molecular Histology

, Volume 45, Issue 1, pp 47–57 | Cite as

ACE2 and FZD1 are prognosis markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of gallbladder

  • Jinghe Li
  • Zhu-lin Yang
  • Xuebao Ren
  • Qiong Zou
  • Yuan Yuan
  • Lufeng Liang
  • Meigui Chen
  • Senlin Chen
Original Paper


The clinicopathological characteristics of squamous cell/adenosquamous carcinoma (SC/ASC) of the gallbladder have not been well documented, and no prognosis marker has been identified because of the rare occurrence of this gallbladder cancer subtype. In this study, we examined ACE2 and FZD1 expression in 46 SC/ASCs and 80 adenocarcinomas using immunohistochemistry and further analyzed their correlations with clinicopathological characteristics. We demonstrated that positive FZD1 and negative ACE2 expression were significantly associated with large tumor size, high TNM stage, lymph node metastasis and invasion of SC/ASC and AC. Univariate Kaplan–Meier analysis showed that positive FZD1 and negative ACE2 expression as well as differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical curability were closely associated with decreased overall survival in both SC/ASC (p < 0.001) and AC (p < 0.001) patients. The average survival time in SC/ASC and AC patients with FZD1ACE2+ expression was significantly longer than that in patients with FZD1+ACE2 or FZD1+ACE2+ (p < 0.01). Multivariate Cox regression analysis showed that positive FZD1 and negative ACE2 expression are independent poor-prognostic factors for both SC/ASC and AC patients. In addition, FZD1 expression positively, but ACE2 expression negatively correlated with the expression of CA19-9 in SC/ASC and AC. Our study suggested that positive FZD1 and negative ACE2 expression are closely related to the expression of CA19-9; clinical, pathological, and biological behaviors; as well as poor-prognosis of gallbladder cancer.


Gallbladder cancer Adenocarcinoma Squamous cell carcinoma Adenosquamous carcinoma ACE2 FZD1 CA19-9 Prognosis Metastasis 


Conflict of interest

The authors declared no conflicts of interest.


  1. Badiglian Filho L, Oshima CT, De Oliveira LF, De Oliveira CH, De Sousa DR, Gomes TS, Gonçalves WJ (2009) Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 21:313–320PubMedGoogle Scholar
  2. Bartlett DL (2000) Gallbladder cancer. Semin Surg Oncol 19:145–155PubMedCrossRefGoogle Scholar
  3. Bernardi S, Zennaro C, Palmisano S, Velkoska E, Sabato N, Toffoli B, Giacomel G, Buri L, Zanconati F, Bellini G, Burrell LM, De Manzini N, Fabris B (2012) Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 13:202–209PubMedCrossRefGoogle Scholar
  4. Cantilena S, Pastorino F, Pezzolo A, Chayka O, Pistoia V, Ponzoni M, Sala A (2011) Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget 2:976–983PubMedGoogle Scholar
  5. Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299PubMedCrossRefGoogle Scholar
  6. Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B, Xiang Y, Che J, Cao H, Fei X, Qiu W (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 23:941–948PubMedGoogle Scholar
  7. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, Mühlethaler-Mottet A, Gross N (2009) The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 28:2245–2256PubMedCrossRefGoogle Scholar
  8. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R (2004) Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106–111PubMedCrossRefGoogle Scholar
  9. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T (2002) Expression of Wnt ligands and frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55:220–226PubMedCentralPubMedCrossRefGoogle Scholar
  10. Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S, Kikkawa F (2006) Manipulating the angiotensin system—new approaches to the treatment of solid tumours. Expert Opin Biol Ther 6:243–255PubMedCrossRefGoogle Scholar
  11. Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331–342PubMedCrossRefGoogle Scholar
  12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  13. Jiang XT, Tao HQ, Zou SC (2004) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3:464–468PubMedGoogle Scholar
  14. Jiexian J, Xiaogin X, Lili D, Baoguo T, Ting S, Xianwen Z, Cunzhi H (2013) Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. Int J Biol Markers 28:192–200PubMedCrossRefGoogle Scholar
  15. Kimura Y, Furuhata T, Mukaiya M, Kihara C, Kawakami M, Okita K, Yanai Y, Zenbutsu H, Satoh M, Ichimiya S, Hirata K (2003) Frequent beta-catenin alteration in gallbladder carcinomas. J Exp Clin Cancer Res 22:321–328PubMedGoogle Scholar
  16. Kondo M, Dono K, Sakon M, Shimizu J, Nagano H, Nakamori S, Umeshita K, Wakasa K, Monden M (2002) Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology 49:1230–1234PubMedGoogle Scholar
  17. Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J, Varona A (2010) Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 165:218–223PubMedCrossRefGoogle Scholar
  18. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE (2007) Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 67:2809–2815PubMedCrossRefGoogle Scholar
  19. Merle P, Kim M, Herrmann M, Gupte A, Lefrançois L, Califano S, Trépo C, Tanaka S, Vitvitski L, de la Monte S, Wands JR (2005) Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 43:854–862PubMedCrossRefGoogle Scholar
  20. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF (2004) Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 25:1337–1342PubMedGoogle Scholar
  21. Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R (2012) CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol 33:799–807PubMedCrossRefGoogle Scholar
  22. Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M (1994) Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res 85:389–399PubMedCrossRefGoogle Scholar
  23. Ootani T, Shirai Y, Tsukada K, Muto T (1992) Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer 69:2647–2652PubMedCrossRefGoogle Scholar
  24. Park SB, Kim YH, Rho HL, Chae GB, Hong SK (2012) Primary carcinosarcoma of the gallbladder. J Korean Surg Soc 82:54–58PubMedCentralPubMedCrossRefGoogle Scholar
  25. Plemenos MF, Dimas C, Kotsios A, Gennatas K, Pafiti AK (2004) Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinomas. J BUON 9:73–76PubMedGoogle Scholar
  26. Rashid A, Gao YT, Bhakta S, Shen MC, Wang BS, Deng J, Fraumeni JF Jr, Hsing AW (2001) Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 61:3406–3409PubMedGoogle Scholar
  27. Reid KM, Ramos-De la Medina A, Donohue JH (2007) Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 11:671–681PubMedCrossRefGoogle Scholar
  28. Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, Saka B, Losada H, Bagci P, Adsay NV (2011) Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol 24:1069–1078PubMedCrossRefGoogle Scholar
  29. Salsano E, Paterra R, Figus M, Menghi F, Maderna E, Pollo B, Solero CL, Massimi L, Finocchiaro G (2012) Expression profile of frizzled receptors in human medulloblastomas. J Neurooncol 106:271–280PubMedCrossRefGoogle Scholar
  30. Santos RA, Campagnole-Santos MJ, Andrade SP (2000) Angiotensin-(1-7): an update. Regul Pept 91:45–62PubMedCrossRefGoogle Scholar
  31. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA (2009) Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 8:1676–1683PubMedCentralPubMedCrossRefGoogle Scholar
  32. Turner AJ, Tipnis SR, Guy JL, Rice GI, Hooper NM (2001) ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80:346–353CrossRefGoogle Scholar
  33. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y (2008) Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 10:697–705PubMedCentralPubMedGoogle Scholar
  34. Vinson GP, Ho MM, Puddefoot JR (1995) The distribution of angiotensin II type 1 receptors, and the tissue renin–angiotensin systems. Mol Med Today 1:35–39PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Jinghe Li
    • 1
  • Zhu-lin Yang
    • 2
  • Xuebao Ren
    • 2
  • Qiong Zou
    • 3
  • Yuan Yuan
    • 3
  • Lufeng Liang
    • 4
  • Meigui Chen
    • 5
  • Senlin Chen
    • 6
  1. 1.Department of Pathology, Basic School of MedicineCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Research Laboratory of Hepatobiliary Diseases, Second Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  3. 3.Department of Pathology, Third Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  4. 4.Department of Hepatobiliary and Pancreatic SurgeryHunan Provincial People’s HospitalChangshaPeople’s Republic of China
  5. 5.Department of PathologyLoudi Central HospitalLoudiPeople’s Republic of China
  6. 6.Department of PathologyHunan Provincial Tumor HospitalChangshaPeople’s Republic of China

Personalised recommendations